18F-FAPI PET/CT for Early Detection and Severity Assessment of Intestinal Fibrosis in a Mouse Model
- PMID: 40349210
- DOI: 10.1093/ibd/izaf086
18F-FAPI PET/CT for Early Detection and Severity Assessment of Intestinal Fibrosis in a Mouse Model
Abstract
Background: To investigate the feasibility of using 18F-fibroblast activation protein (FAP) inhibitor positron emission tomography/computed tomography (18F-FAPI PET/CT) to detect intestinal fibrosis in its early stages and identify its severity in a mouse model.
Methods: A dextran sulfate sodium (DSS)-induced mouse model of intestinal fibrosis was established. To detect pro-inflammatory cytokines and histopathology, blood and intestinal lesion samples were collected after 18F-FAPI PET/CT scanning (3.7 MBq/mice) at 3, 6, 9, and 12 weeks post-initial exposure to DSS. Correlation and diagnostic efficacy were explored between 18F-FAPI uptake and FAP expression or fibrosis score in early, late, and entire stages of intestinal fibrosis.
Results: 18F-FAPI uptake was positively correlated with FAP expression throughout entire stages of intestinal fibrosis (r = 0.90). However, a weak correlation between 18F-FAPI uptake and fibrosis score (r = 0.49), and moderate diagnostic performance of 18F-FAPI PET for fibrotic severity (area under the receiver-operating characteristic curve [AUC] = 0.79) were found throughout the entire stages. Interestingly, in the early stages, 18F-FAPI PET effectively distinguished the degree of intestinal fibrosis (AUC = 0.95), and was strongly correlated with fibrosis score (r = 0.89). In the late stages, the diagnostic efficacy (AUC = 0.46) and correlation (r = -0.20) drastically decreased.
Conclusions: As Crohn's disease (CD) with intestinal fibrosis progresses, 18F-FAPI uptake is high in the early stages and then gradually decreases. Activated fibroblasts appear more frequently in the early stages of intestinal fibrosis indicates that 18F-FAPI PET has a great potential for early identification of intestinal fibrosis and provides new insights into treatment decision-making in CD patients.
Keywords: 18F-fibroblast activation protein inhibitor; Crohn’s disease; fibrosis; mouse model of intestinal fibrosis; positron emission tomography.
Plain language summary
18F-fibroblast activation protein inhibitor positron emission tomography/computed tomography has a great 18F-fibroblast activation protein inhibitor positron emission tomography/computed tomography (18F potential for early identification of intestinal fibrosis and provides new insights into treatment decision-making and efficacy monitoring in Crohn’s disease.
© The Author(s) 2025. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68Ga-FAPI-LM3 PET.Mol Pharm. 2024 Jul 1;21(7):3684-3692. doi: 10.1021/acs.molpharmaceut.4c00405. Epub 2024 Jun 20. Mol Pharm. 2024. PMID: 38899595 Free PMC article.
-
Discrimination between Inflammatory and Fibrotic Activity in Crohn's Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging.Visc Med. 2025 Feb;41(1):1-13. doi: 10.1159/000542160. Epub 2024 Dec 20. Visc Med. 2025. PMID: 39927190
-
Radio-labelled fibroblast activation protein inhibitors in interstitial lung diseases - a systematic review.Autoimmun Rev. 2025 Aug 29;24(9):103856. doi: 10.1016/j.autrev.2025.103856. Epub 2025 Jun 20. Autoimmun Rev. 2025. PMID: 40544983 Review.
-
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.J Nucl Med. 2024 Dec 3;65(12):1952-1958. doi: 10.2967/jnumed.124.268037. J Nucl Med. 2024. PMID: 39477498 Free PMC article.
-
The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update.Semin Nucl Med. 2025 Sep;55(5):701-709. doi: 10.1053/j.semnuclmed.2025.06.011. Epub 2025 Jul 16. Semin Nucl Med. 2025. PMID: 40675899 Review.
MeSH terms
Substances
Grants and funding
- 2023GDRC002/Chongqing Science and Health Joint Medical Research Project-Young and Middle-aged High-level Talent Project
- 2024NSCQ-MSX3234/Natural Science Foundation of Chongqing
- 2022XJS29/Science and Technology Innovation Ability Enhancement Project of Army Medical University
- CSTC2015YFPT-gcjsyjzx0175/Chongqing Clinical Research Centre of Imaging and Nuclear Medicine
- 2023XLC06/Science and Technology Innovation Ability Enhancement Project of Army Medical University
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous